Allegations have arisen claiming that these drugs, which are glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may cause severe gastrointestinal side effects, including gastroparesis, also known as stomach paralysis
In some cases, switching to a different medication formulation may be appropriate if reactions are related to specific excipients
Even modest reductions in systolic blood pressure have been associated with lower risks of stroke, heart attack, and other cardiovascular complications
GLP-1 and GLP-1 receptor agonists may represent novel drugs of therapeutic intervention with potential value, providing an alternative to the existing therapy for stroke
Keon of the CGPA, which represents 17 companies, said the challenge is that Health Canada unlike some of its international counterparts hasnt published blanket guidance about what should be included in generic semaglutide applications